Next Article in Journal
The Optimization of a Dimenhydrinate Transdermal Patch Formulation Based on the Quantitative Analysis of In Vitro Release Data by DDSolver through Skin Penetration Studies
Previous Article in Journal
Antibacterial, Antibiofilm, and Antischistosomal Activity of Montrichardia linifera (Arruda) Schott (Araceae) Leaf Extracts
Article

Cumulative Risks of Excipients in Pediatric Phytomucolytic Syrups: The Implications for Pharmacy Practice

1
Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, 61057 Kharkiv, Ukraine
2
Department of Propedeutics of Pediatric Diseases, National Pirogov Memorial Medical University, 21018 Vinnytsya, Ukraine
*
Author to whom correspondence should be addressed.
Academic Editor: Helen D. Skaltsa
Sci. Pharm. 2021, 89(3), 32; https://doi.org/10.3390/scipharm89030032
Received: 13 May 2021 / Revised: 26 June 2021 / Accepted: 1 July 2021 / Published: 5 July 2021
Expectorant phytomucolytic syrups are widely used pediatric OTC-medicines. Physicians, pediatricians, and pharmacists are traditionally concerned with the efficacy of the active ingredients in cough syrups, and rarely consider the safety aspects of excipients that however are not absolutely “inactive” and are proved to initiate some negative reactions and interactions with other drugs. This paper presents a review, categorization, and comparative analysis of the safety profile of excipients contained in the 22 best-selling OTC pediatric phytomucolytic syrups available in pharmaceutical markets in Ukraine and Germany and proposes an approach to the consideration of the excipients’ safety risks for a pharmacist in the process of pharmaceutical care. The study has revealed that only one of the twenty-two analyzed syrups does not contain any potentially harmful excipients. The results of this analysis were used for developing a specific decision tool for pharmacists that can be used for minimizing excipient-initiated reactions when delivering OTC phytomucolytic syrups for children. View Full-Text
Keywords: phytomucolytic syrup; excipients; pharmaceutical care; pediatric medicines phytomucolytic syrup; excipients; pharmaceutical care; pediatric medicines
Show Figures

Figure 1

MDPI and ACS Style

Zupanets, K.O.; Shebeko, S.K.; Ratushna, K.L.; Katilov, O.V. Cumulative Risks of Excipients in Pediatric Phytomucolytic Syrups: The Implications for Pharmacy Practice. Sci. Pharm. 2021, 89, 32. https://doi.org/10.3390/scipharm89030032

AMA Style

Zupanets KO, Shebeko SK, Ratushna KL, Katilov OV. Cumulative Risks of Excipients in Pediatric Phytomucolytic Syrups: The Implications for Pharmacy Practice. Scientia Pharmaceutica. 2021; 89(3):32. https://doi.org/10.3390/scipharm89030032

Chicago/Turabian Style

Zupanets, Kateryna O., Sergii K. Shebeko, Kseniia L. Ratushna, and Oleksandr V. Katilov 2021. "Cumulative Risks of Excipients in Pediatric Phytomucolytic Syrups: The Implications for Pharmacy Practice" Scientia Pharmaceutica 89, no. 3: 32. https://doi.org/10.3390/scipharm89030032

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop